

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association between LKB1 expression and prognosis of patients with solid tumors: an updated systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027185
Article Type:	Research
Date Submitted by the Author:	15-Oct-2018
Complete List of Authors:	Ren, Yun; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department; Guangxi Medical University Zhao, Feng; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department; Guangxi Medical University Mo, Han; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Jia, Rong; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Tang, Juan; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Zhao, Xin; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Wei, Jue; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department; Guangxi medical university Huo, Rong; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Li, Qiu; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department You, Xue; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center
Keywords:	LKB1, STK11, liver kinase B1, prognosis



1
2
3
4 **Association between LKB1 expression and prognosis of patients with solid tumors: an**
5
6 **updated systematic review and meta-analysis**
7

8
9 Yun-Hong Ren^{1,3*}, Feng-Juan Zhao^{1,3*}, Han-Yue Mo^{1*}, Rong-Rong Jia¹, Juan Tang¹, Xin-Hua
10 Zhao¹, Jue-Ling Wei^{1,3}, Rong-Rui Huo¹, Qiu-Qin Li¹, Xue-Mei You^{1,2}
11
12

13
14 * These authors contributed equally to this work.
15
16

17
18
19
20 **Correspondence:**

21 Xue-Mei You

22
23
24
25 Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University,
26 He Di Rd #71, Nanning 530021, People's Republic of China
27

28
29
30 Email: You_XueMei77@163.com (X.-M.Y)
31

32
33 Telephone: +86 771 533 0855
34

35
36 Fax: +86 771 531 2000
37
38
39
40
41

42 **Abstract**
43
44

45 **Objectives.** Liver kinase B1 (LKB1) is considered a tumor suppressor that can control cell
46 growth and metabolism. Whether LKB1 expression levels are related to clinicopathology and
47 prognosis is controversial. This review aimed to quantitatively examine the latest evidence on
48 this question.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Methods.** Eligible studies were identified through a literature search up to June 15, 2018 in the
5
6 following databases: Embase, PubMed, Web of Science, China National Knowledge
7
8 Infrastructure and Wan Fang. Relevant data were meta-analyzed for overall survival (OS),
9
10 disease-free survival (DFS), recurrence-free survival (RFS) and various clinical parameters.
11
12
13

14
15 **Results.** The systematic review included 25 studies containing 6,012 patients with solid tumors.
16
17 Compared to patients with high LKB1 expression, patients with low expression showed
18
19 significantly shorter OS in univariate analysis (HR1.61, 95%CI 1.36-1.92, P<0.01) and
20
21 multivariate analysis (HR1.61, 95%CI 1.26-2.06, P<0.01). In contrast, the two groups showed
22
23 similar DFS in univariate analysis (HR1.49, 95%CI 0.73-3.01, P=0.27) as well as similar RFS in
24
25 univariate analysis (HR1.44, 95%CI 0.65-3.17, P=0.37) and multivariate analysis (HR1.02,
26
27 95%CI 0.42-2.47, P=0.97). Patients with low LKB1 expression showed significantly worse
28
29 tumor differentiation (OR1.71, 95%CI 1.14-2.55, P<0.01), larger tumors (OR1.68, 95%CI
30
31 1.24-2.27, P<0.01), earlier lymph node metastasis (OR 1.43, 95%CI 1.26-1.62, P<0.01) and
32
33 more advanced TNM stage (OR 1.80, 95%CI 1.56-2.07, P<0.01).
34
35
36
37
38
39
40
41

42 **Conclusion.** Low LKB1 expression predicts shorter OS, worse tumor differentiation, larger
43
44 tumors, earlier lymph node metastasis and more advanced TNM stage. Low LKB1 expression
45
46 may be a useful biomarker of poor clinicopathology and prognosis.
47
48
49

50 **Strengths and limitations of this study.** (1) Meta-analysis of 25 studies involving 6,012 patients
51
52 in six countries found the evidence of a relationship between LKB1 expression and solid tumor
53
54 prognosis and clinicopathology.
55
56
57

1
2
3
4 (2) Subgroup analysis was performed after stratifying the results based on multivariate analysis,
5
6 type of LKB1 assay, country, cancer type, and intracellular location of LKB1 staining that was
7
8 examined.
9

10
11
12 (3) Results interpretation should pay attention to the study of high heterogeneity.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

The serine/threonine kinase liver kinase B1 (LKB1), also known as STK11, was originally observed to be mutated in the genes of patients with Peutz-Jeghers syndrome[1]. LKB1 is often mutated in lung, breast, gastric and other cancers [2-4]. LKB1 plays roles in multiple cellular processes, including cell structure control, cell cycle regulation, apoptosis and cellular metabolism[5-7]. LKB1 phosphorylates multiple substrates, including AMPK, to act as a tumor suppressor to restrict tumorigenesis and metastasis[8]. Mice with a Treg-specific deletion of LKB1 develop a fatal inflammatory disease, and LKB1 in Treg cells acts not through signalling by AMPK or the mammalian target of rapamycin complex1 (mTORC1) and Hif-1, but through signalling involving pd-1 and TNF receptor proteins[9]. LKB1 deficiency can render tumor cells sensitive to metabolic stress, which may turn out to be an anti-tumor strategy[10].

Although several studies have examined the role of LKB1 in tumor inhibition, its role in the prognosis of solid tumors has not been conclusively determined. Several studies suggest that decreased LKB1 expression indicates poor prognosis. In fact, meta-analysis showed that decreased LKB1 expression in patients with solid tumors may be related to poor prognosis and serve as a predictor of clinicopathological prognostic factors[11]. However, other studies have not reproduced these findings, and some have even suggested that decreased LKB1 may correlate with favorable survival.

1
2
3
4 Therefore we systematically reviewed and meta-analyzed the relevant literature to understand the
5
6 current evidence about a relationship between LKB1 expression and prognosis in patients with
7
8 solid tumors.
9
10

11 12 13 14 15 16 **Materials and Methods**

17 18 19 *Literature search strategy*

20
21
22 The following databases were searched through June 15, 2018 to identify studies of LKB1
23
24 expression and survival in solid tumors: PubMed, Embase, Web of Science, the Chinese National
25
26 Knowledge Infrastructure, and Wang Fang. Searches were carried out using terms such as LKB1,
27
28 STK11, liver kinase B1, prognosis, prognostic, survival, and overall survival. For example, we
29
30 searched PubMed using the following strategy: (LKB1[tw] OR STK11[tw] OR "liver kinase
31
32 B1"[tw] OR "serine-threonine kinase 11"[tw]) AND ("prognosis"[MeSH Terms] OR
33
34 prognoses[tw] OR prognostic[tw] OR "prognostic factor"[tw] OR "prognostic factors"[tw] OR
35
36 factor[tw] OR factors[tw] OR outcome[tw] OR survival[tw] OR metastases[tw] OR
37
38 metastasis[tw] OR migration[tw] OR transplantation[tw] OR transfer[tw] OR shift[tw] OR
39
40 divert[tw] OR recurrence[tw] OR relapse[tw] OR reappear[tw] OR recur[tw] OR
41
42 recidivation[tw] OR invasion[tw]).
43
44
45
46
47
48
49
50

51 52 53 54 55 56 *Study inclusion and exclusion criteria*

1
2
3
4 Studies were considered eligible if they met the following criteria:(1) LKB1 expression in cancer
5
6 tissue (obtained via surgery or biopsy) was measured by immunohistochemistry or Western
7
8 blotting; (2)the association was studied between LKB1 expression and clinicopathological
9
10 characteristics, overall survival (OS), disease-free survival (DFS), or recurrence-free survival
11
12 (RFS) of patients with solid tumors; (3)sufficient data were published for calculating an odds
13
14 ratio (OR) or hazard ratio (HR) and 95% confidence interval (CI); and (4) the study was
15
16 published as a full-text article in English or Chinese. If we retrieved multiple studies conducted
17
18 by the same research group and involving overlapping patient populations, only the most recent
19
20 or most complete study was included in the meta-analysis. Articles were excluded if they (1)
21
22 were duplicate publications; (2) were case reports, reviews, letters or animal studies; or (3) did
23
24 not report survival outcomes.
25
26
27
28
29
30
31
32
33
34
35
36

37 *Study quality assessment*

38
39
40 Two reviewers independently assessed the quality of included studies using the standard
41
42 Newcastle–Ottawa scale (NOS) from 0 to 9. NOS scores of 9-7 were defined as high quality, 6-4
43
44 as intermediate quality, and 3-1 as low quality.
45
46
47
48
49
50
51

52 *Data extraction*

53
54
55 Two researchers (YHR and FJZ) independently screened all titles and abstracts identified in the
56
57
58
59
60

1
2
3
4 initial search. Articles remaining after this screen were read in full and assessed for eligibility.
5
6 The following types of data were extracted: (1) name of first author, publication year, country,
7
8 type of cancer and number of patients; (2) patient age, gender, follow-up time, type of LKB1
9
10 assay, intracellular location where LKB1 staining was examined, LKB1 cut-off value for
11
12 classifying expression as high or low, survival data (OS, DFS, RFS), statistical method used to
13
14 analyze survival data; (3) tumor differentiation, tumor size, lymph node metastasis and TNM
15
16 stage. All data were cross-checked by two researchers, and disagreements were resolved by a
17
18 third reviewer (JHZ). If study information was incomplete or unclear, we contacted the
19
20 corresponding author in an attempt to collect accurate information.
21
22
23
24
25
26
27
28
29
30

31 *Statistical analysis*

32
33
34
35 Correlation between LKB1 expression and OS of patients with solid tumors was evaluated in
36
37 terms of HR and 95%CI. If a study showed Kaplan-Meier survival curves but not HRs with
38
39 95%CI, data were extracted from survival curves using Engauge Digitizer 4.1
40
41 (sourceforge.net/projects/digitizer) and the Tierney table
42
43 (www.biomedcentral.com/content/supplementary/1745-6215-8-16S1.xls).Correlation
44
45
46
47
48
49 between LKB1 expression and clinicopathological characteristics of patients with solid tumors
50
51 was evaluated in terms of OR and 95%CI.
52
53
54
55
56
57
58
59
60

1
2
3
4 HRs and ORs were meta-analyzed using the random-effects model in Review Manager 5.3
5
6 (Cochrane Collaboration, Copenhagen, Denmark). P values were two-sided and values <0.05
7
8 were considered statistically significant.
9
10

11
12
13
14
15
16 I^2 was used to assess statistical heterogeneity. If $I^2 > 50\%$, heterogeneity was considered to exist
17
18 among all included studies, and we conducted a subgroup analysis to investigate its possible
19
20 source. If $I^2 < 50\%$, heterogeneity among all included studies was regarded as insignificant, and
21
22 data were directly pooled.
23
24
25
26
27
28
29

30
31 To assess the stability of our meta-analysis results, we conducted a sensitivity analysis by
32
33 excluding individual studies one at a time and recalculating the pooled HR or P value for the
34
35 remaining studies. Potential for publication bias was assessed by examining funnel plots of
36
37 survival data.
38
39
40
41
42
43
44

45 **Results**

46
47
48 A total of 4,838 potentially relevant studies were identified in literature searches, of which 3,374
49
50 were excluded as duplicate publications. After screening titles and abstracts, 50 studies were read
51
52 in full, leading to 25 that were included in the meta-analysis [12-36] (Fig.1). Data from all 25
53
54
55
56
57
58
59
60

1
2
3
4 studies were meta-analyzed to examine the potential correlation of LKB1 expression with
5
6 clinicopathological characteristics. Data from 24 studies were meta-analyzed to examine the
7
8 potential correlation between LKB1 expression and OS. Data from only one study were used to
9
10 analyze the potential correlation between LKB1 expression and RFS.
11
12
13
14
15
16
17

18 *Description of studies*

19
20
21
22 The 25 studies in the systematic review involved 6,012 patients from six countries: China, USA,
23
24 France, UK, Canada, and Egypt. Data on OS were reported in 24 studies, data on RFS in five
25
26 studies, and data on DFS in four studies. Patients covered a range of cancers, including cancers
27
28 of the lung, breast, prostate or pancreas; gastric cancer; hepatocellular carcinoma; esophagus
29
30 squamous cancer; colorectal cancer; glioma; and laryngeal squamous cell carcinoma. Tables 1-2
31
32 summarize the characteristics of the included studies. Table 3 lists clinicopathological
33
34 characteristics and LKB1 expression. Eight studies had an NOS score of 8; 11 studies, 7; 6
35
36 studies, 6; and 3 studies, 5 (Table 1).
37
38
39
40
41
42
43
44
45
46

47 Of the 25 studies, 16 reported HRs from multivariate analysis, which we used directly. For the
48
49 nine remaining studies, we estimated HRs for OS, DFS, and RFS from survival curves and
50
51 Tierney's table.
52
53
54
55
56
57
58
59
60

Association between LKB1 expression and OS

Given heterogeneity among the studies ($I^2=76.0\%$, $P<0.001$), a random-effects model was used to meta-analyze the data. The pooled HR describing OS for patients with low LKB1 expression relative to OS for patients with high expression is shown in Fig.2A. Decreased LKB1 expression was significantly associated with OS: low expression was associated with significantly higher risk of poor survival (HR1.61, 95%CI 1.36-1.92, $P<0.01$).

To assess the predictive role of decreased LKB1, subgroup analysis was performed after stratifying the results based on multivariate analysis, type of LKB1 assay, country, cancer type, and intracellular location of LKB1 staining that was examined. Subgroup analysis based on multivariate analysis showed that decreased LKB1 expression was related to poor OS (HR 1.61, 95%CI 1.26–2.06, $P <0.001$; Fig.2B). This relationship was observed for the following cancer types: lung cancer (HR 2.07, 95%CI 1.60-2.69, $P<0.01$), pancreatic cancer (HR 2.16, 95%CI 1.53-3.05, $P<0.001$), gastric cancer (HR 2.19, 95%CI 1.60-3.01, $P<0.01$), and breast cancer (HR1.26, 95%CI 1.15-1.37, $P<0.01$). However, this relationship was not observed in the case of hepatocellular carcinoma (HR1.27, 95%CI 0.84-1.94, $P=0.26$).

Among Asian patients, decreased LKB1 expression was associated with significantly shorter OS (HR1.71, 95%CI 1.42-2.07, $P<0.01$); this relationship was not observed among non-Asian

1
2
3
4 patients (HR1.15, 95%CI 0.63-2.08, P=0.65).
5
6
7
8
9

10 Pooled HR for the subgroup of patients tested by anti-LKB1 immunohistochemistry was 1.58
11 (95%CI 1.33–1.89, P<0.01). Low LKB1 expression based on cytoplasmic staining predicted
12 significant adverse prognosis (HR1.78, 95%CI 1.49-2.13, P<0.01). This relationship was not
13 observed when the judgment of low LKB1 expression was based on nuclear staining (HR1.25,
14 95%CI 0.85-1.85, P=0.26).
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Details of the subgroup analysis are listed in Table 4. The results of the sensitivity analysis
29 showed that the exclusion of each single study did not alter the results significantly (data not
30 shown). These results suggest that our meta-analysis gave credible results.
31
32
33
34
35
36
37
38
39

40 *Association of LKB1 expression with DFS and RFS*

41
42

43 Studies showed significant heterogeneity, so data were meta-analyzed using a random-effect
44 model. Low LKB1 expression did not show a significant association with RFS based on
45 univariate analysis (HR 1.44, 95%CI 0.65-3.17, P=0.37) or multivariate analysis (HR 1.02,
46 95%CI 0.42-2.47, P=0.97; Fig.2C). Similarly, no significant correlation was observed between
47 LKB1 expression and DFS based on univariate analysis and random-effect meta-analysis (HR
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1.49, 95%CI 0.73-3.01, P=0.27; Fig. 2D).
5
6
7
8
9

10 *Association between LKB1 expression and clinicopathological characteristics*

11
12
13
14 Meta-analysis of the relationship between LKB1 expression and clinicopathological
15 characteristics (Fig.3) failed to show a significant association of decreased LKB1 expression
16 with age (OR 0.78, 95%CI 0.57-1.05, P=0.10) or sex (OR 0.97, 95%CI 0.78-1.19, P=0.76). In
17 contrast, low LKB1 expression was significantly related to worse differentiation (OR 1.17,
18 95%CI 1.14-2.55, P<0.01), deeper invasion (OR 1.68, 95%CI 1.24-2.27, P<0.01), earlier lymph
19 node metastasis (OR 1.43, 95%CI 1.26-1.62, P<0.01), and more advanced clinical stage (OR
20 1.80, 95%CI 1.56-2.07, P<0.01).
21
22
23
24
25
26
27
28
29
30
31
32

33 Results are shown as individual and pooled OR with 95% confidence intervals
34
35

36 *Publication bias*

37
38
39
40 Funnel plots of OS appeared asymmetric (Fig.4), suggesting the possibility of publication bias
41 among the included studies.
42
43
44
45
46
47
48
49

50 **Discussion**

51
52
53 This meta-analysis suggests that among patients with many kinds of solid tumors, low LKB1
54 expression is associated with worse OS, whereas LKB1 expression does not appear to
55
56
57
58
59
60

1
2
3
4 significantly influence DFS or RFS. This suggests that low LKB1 expression may be a predictor
5
6 of unfavorable prognosis. In fact, the available evidence suggests an association of low LKB1
7
8 expression with worse tumor differentiation, deeper invasion, more advanced clinical stage, and
9
10 earlier metastasis to lymph nodes and other organs. These findings are consistent with previous
11
12 conclusions [11], and they were confirmed in our data set using sensitivity analysis.
13
14
15
16
17
18
19
20

21 Some potentially interesting findings emerged from subgroup analyses conducted after
22
23 stratifying the data according to various criteria. Our meta-analysis linked low LKB1 expression
24
25 with poor prognosis in Asians but not in non-Asians, which may reflect genetic and
26
27 environmental differences. While low LKB1 expression was associated with worse prognosis in
28
29 patients with certain types of cancer (lung, gastric, pancreatic, breast), this was not the case in
30
31 patients with hepatocellular carcinoma. This difference may relate to different co-morbidities
32
33 associated with the types of cancer. Lung cancer, stomach cancer, breast cancer, and pancreatic
34
35 cancer have high incidence rates around the world, and more studies have been done. The
36
37 association between low expression of LKB1 and poor prognosis was observed when low
38
39 expression was based on cytoplasmic staining, but not when it was based on nuclear staining.
40
41
42 The reason may be that the regulation of mTORC1 by LKB1 and AMPK occurs on the exterior
43
44 of RAB7/LAMP1-positive lysosomal membranes [37]. In this regulation, LKB1 phosphorylates
45
46 and activates cell energy-sensing AMPK, which in turn negatively affects TORC1, which is
47
48 important for controlling energy metabolism, cell survival and cell growth under conditions of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 metabolic stress, such as nutrient deficiency. Further studies are needed to elucidate the
5
6 mechanism of action of LKB1.
7
8
9

10 Our meta-analysis suggests that at least in many types of solid tumors, LKB1 acts as a tumor
11
12 suppressor. This is consistent with several studies in the literature. For example, a decrease in
13
14 LKB1 expression as a result of HBx-mediated p53 inactivation may be responsible for colony
15
16 formation and invasiveness in hepatocellular carcinoma [41]. LKB1 deficiency in some tumors
17
18 may be associated with up-regulation of glutamate
19
20 dehydrogenase 1, which activates CamKK2 and its downstream effector AMPK to increase
21
22 metastatic potential [42]. LKB1 loss may drive ovarian serous tumorigenesis by disrupting
23
24 apical-basal polarity in the presence of mutated p53 in fallopian tube cells [39]. On the one hand,
25
26 several studies have suggested an oncogenic role for LKB1 and AMPK under certain
27
28 conditions [38], such as when class III phosphatidylinositol-3-OH kinase is inactivated [40].
29
30 Further work is needed to clarify under what conditions LKB1 acts as a tumorigenic or
31
32 tumor-suppressing molecule.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 The results of our meta-analysis should be interpreted with caution given several limitations.
47
48 First, we had to assess OS, DFS and/or RFS from Kaplan-Meier survival curves in several
49
50 studies, such that HRs and 95% CIs were estimated indirectly. Second, studies showed substantial
51
52 heterogeneity for outcomes, although we did attempt to minimize the effects of such
53
54
55
56
57
58
59
60

1
2
3
4 heterogeneity by using a random-effect meta-analysis model, performing subgroup analyses and
5
6 checking results through sensitivity analysis. Third, there is no consensus on LKB1 cut-off
7
8 values for defining expression as low or high, which may influence conclusions about
9
10 correlations and their clinical significance. Fourth, the funnel plots suggest the potential for
11
12 publication bias. This may reflect the generally observed bias toward publication of positive
13
14 findings. Fifth, our meta-analysis did not account for numerous other factors that may also affect
15
16 prognosis, such as co-morbidities and treatment history. In most cases, this information was not
17
18 reported in the included studies.
19
20
21
22
23
24

25 Our results justify the design of rigorous *in vitro* and animal studies designed to explore how
26
27 LKB1 influences the prognosis of various types of solid cancers. Ultimately this work should be
28
29 extended through human studies, preferentially randomized controlled trials.
30
31
32
33
34
35
36
37

38 **Conclusions**

39
40
41 The available evidence links low LKB1 expression with poor prognosis in patients with various
42
43 types of solid tumors. This suggests that LKB1 may be a biomarker for various cancers. These
44
45 findings should be verified and extended in human studies, and the mechanisms underlying the
46
47 association of LKB1 expression and prognosis should be explored.
48
49
50
51
52
53
54

55 **Author affiliations**

- 1
- 2
- 3
- 4 1. Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical
- 5 University, Nanning, China
- 6
- 7 2. Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research
- 8 Center, Nanning, China
- 9
- 10
- 11 3. Guangxi medical university, Nanning, China
- 12

13 **Contributors** YXM and MHY designed the study. ZFJ, MHY and JRR conduct
14 systematic search, search literature and extract data. RYH analyzed the data. RYH and ZFJ wrote
15 the first draft of the article. TJ, ZXH, WJL and HRR contributed significant knowledge content
16 and critical expertise and revisions to the manuscript.
17
18
19
20
21

22 **Funding** This work was supported by the Graduate Course Construction Project of Guangxi
23 Medical University (YJSA2017014), the Foundation Ability Enhancement Project for Young
24 Teachers in Guangxi Universities (2018KY0122, 2017KY0098), the Guangxi Natural Science
25 Foundation (2018GXNSFBA138018), the Research and Development Program of Guangxi
26 science and technology department(AB18126042), the Research and Development of
27 Appropriate Medical and Health Technology Project in Guangxi (S201417-03), and Guangxi
28 Health and Family Planning Commission Chinese Medicine Science and Technology Special
29 Subject (GZLC16-36).
30
31
32
33
34
35
36
37

38 **Competing interests** The authors have declared that no competing interests exist.
39
40

41 **Patient consent** Not required
42
43

44 **Provenance and peer review** Not commissioned; externally peer reviewed
45
46
47

48 **Data sharing statement** No additional data are available.
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Hemminki A. *The molecular basis and clinical aspects of Peutz-Jeghers syndrome*. Cell Mol Life Sci, 1999. 55(5): p. 735-50.
2. Ji H, Ramsey MR, et al. *LKB1 modulates lung cancer differentiation and metastasis*. Nature, 2007. 448(7155): p. 807-10.
3. Zhuang ZG, Di GH, et al. *Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential*. Mol Cancer Res, 2006. 4(11): p. 843-9.
4. Takahashi M, Sakayori M, et al. *A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer*. Journal of Gastroenterology, 2004. 39(12): p. 1210-1214.
5. Amin N, Khan A, et al. *LKB1 regulates polarity remodeling and adherens junction formation in the Drosophila eye*. Proceedings of the National Academy of Sciences, 2009. 106(22): p. 8941-8946.
6. Granot Z, Swisa A, et al. *LKB1 Regulates Pancreatic β Cell Size, Polarity, and Function*. Cell Metabolism, 2009. 10(4): p. 296-308.
7. Lars Kullmann, Krahn MP. *Controlling the master—upstream regulation of the tumor suppressor LKB1*. Oncogene, 2018.
8. Shackelford DB, Shaw RJ. *The LKB1-AMPK pathway: metabolism and growth control in tumour suppression*. Nat Rev Cancer, 2009. 9(8): p. 563-75.
9. Yang K, Blanco DB, et al. *Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling*. Nature, 2017. 548(7669): p. 602-606.
10. Parker SJ, Sevansson RU, et al. *LKB1 promotes metabolic flexibility in response to energy stress*. Metab Eng, 2017. 43(Pt B): p. 208-217.
11. Xiao J, Zou Y, et al. *The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis*. PLoS One, 2016. 11(4): p. e0152674.
12. Ding XM, Li ZP, et al. *Expression and clinical significance of LKB1 protein in lung adenocarcinoma tissues*. Chin J Cancer Prev T Rea T 2005.12(17), 2005: p. 1281-1284.

13. Tsai LH, Chen PM, et al. *LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.* Oncogene, 2014. 33(29): p. 3851-60.
14. Jiang LL, Liang X, et al. *Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.* Oncology Reports, 2014: p. 1931-1938.
15. Calles A, Sholl LM, et al. *Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.* Clin Cancer Res, 2015. 21(12): p. 2851-60.
16. Shen Z, Wen XF, et al. *The Tumor Suppressor Gene LKB1 Is Associated with Prognosis in Human Breast Carcinoma.* Clin Cancer Res, 2002(8): p. 2085-2090.
17. Bouchekioua-Bouzaghrou K, Poulard C, et al. *LKB1 when associated with methylated ERalpha is a marker of bad prognosis in breast cancer.* Int J Cancer, 2014.
18. Chen IC, Chang YC, et al. *Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer.* Sci Rep, 2016. 6: p. 21374.
19. Azim HA, Kassem L, et al. *Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.* Translational Oncology, 2016. 9(2): p. 114-123.
20. Morton JP, Jamieson NB, et al. *LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.* Gastroenterology, 2010. 139(2): p. 586-97, 597 e1-6.
21. Yang JY, Jiang SH, et al. *Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma.* Sci Rep, 2015. 5: p. 10575.
22. Yang XW, Lin T, et al. *Expression of LKB1 protein in gastric cancer tissue and its clinical significance.* Chin Arch Gen Surg, 2012. 6: p. 51-56.
23. Li DZ, Zhou Y, et al. *Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection.* Onco Targets Ther, 2018. 11: p. 1259-1265.
24. Huang Y, Xia L, et al. *Expression of LKB1 and vascular endothelial growth factor in*

- gastric cancer tissue and its clinical significance. *Pract Geriatr*, 2014. 28(9): p. 734-737.
25. Ma LG, Bian SB, et al. *LKB1 inhibits the proliferation of gastric cancer cells by suppressing the nuclear translocation of Yap and beta-catenin*. *Int J Mol Med*, 2016. 37(4): p. 1039-48.
 26. Yin M, Zhang W. et al. *Expression and clinical significance of LKB1 and ZEB1 in gastric cancer tissues*. *Guizhou Medical Journal*, 2017. 41(10): p. 1021-1024.
 27. Huang YH, Chen ZK, et al. *Decreased Expression of LKB1 Correlates with Poor Prognosis in Hepatocellular Carcinoma Patients Undergoing Hepatectomy*. *Asian Pacific Journal of Cancer Prevention*, 2013. 14(3): p. 1985-1988.
 28. Lee SW, Li CF, et al. *Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress*. *Mol Cell*, 2015. 57(6): p. 1022-33.
 29. Wu CC, Wu DW, et al. *Hepatitis B virus X protein represses LKB1 expression to promote tumor progression and poor postoperative outcome in hepatocellular carcinoma*. *Surgery*, 2018.
 30. Wang JH, Zhang K, et al. *Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma*. *Oncotarget*, 2015. 6(22): p. 18906-18920.
 31. Ma JJ, Du YM, et al. *Expression and significance of LKB1 protein in esophageal squamous cell carcinoma*. *Medicine and Philosophy*, 2014. 35(495): p. 65-68.
 32. He TY, Tsai LH, et al. *LKB1 loss at transcriptional level promotes tumor malignancy and poor patient outcomes in colorectal cancer*. *Ann Surg Oncol*, 2014. 21 Suppl 4: p. S703-10.
 33. Lu J, Sun P, et al. *Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients*. *Medical Science Monitor*, 2015. 21: p. 3722-3727.
 34. Huang J, Chen HW, et al. *Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma*. *Oncol Lett*, 2017. 13(3): p. 1688-1694.
 35. He SS, Chen Y, et al. *Loss of LKB1 Expression Decreases the Survival and Promotes Laryngeal Cancer Metastasis*. *J Cancer*, 2017. 8(17): p. 3548-3554.

- 1
2
3
4 36. Sun J, Liang BX, et al. *Decreased Expression of Tumor-suppressor Gene LKB1 Correlates with Poor Prognosis in Human Gastric Cancer*. *Anticancer Research*, 2016. 36: p. 869-876.
5
6
7
8
9 37. Zhang CS, Jiang B, et al. *The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism*. *Cell Metab*, 2014. **20**(3): p. 526-40.
10
11
12
13
14 38. Hardie DG, Alessi DR. *LKB1 and AMPK and the cancer-metabolism link - ten years after*. *BMC Biol*, 2013. 11: p. 36.
15
16
17
18 39. George SH, Milea A, et al. *Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis*. *Oncogene*, 2016. 35(1): p. 59-68.
19
20
21
22
23 40. O'Farrell F, Lobert VH, et al. *Class III phosphatidylinositol-3-OH kinase controls epithelial integrity through endosomal LKB1 regulation*. *Nat Cell Biol*, 2017. 19(12): p. 1412-1423.
24
25
26
27
28 41. Wu CC, Wu DW, et al. *Hepatitis B virus X protein represses LKB1 expression to promote tumor progression and poor postoperative outcome in hepatocellular carcinoma*. *Surgery*, 2018. 163(5): p. 1040-1046.
29
30
31
32
33 42. Jin L, Chun J, et al. *The PLAG1-GDHI Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer*. *Molecular Cell*, 2018. 69(1): p. 87-99.e7.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Main characteristics of included studies and Newcastle-Ottawa scale scores.

Study	Year	Country	Type of cancer	No. cases		Age in yr, median(range)	Follow-up, mo.	NOS score
				Low LKB1	High LKB1			
Ding XM	2005	China	Lung adenocarcinoma	24	38	60.5(32-77)	80	7
Tsai LH	2013	China	Lung adenocarcinomas	44	71	NR	140	7
Jiang LL	2014	China	Non-small cell lung cancer	33	109	58.2(31-84)	71	7
Calles A	2015	USA	Lung adenocarcinoma	42	84	63.5(30-84)	60	7
Shen Z	2002	China	Breast carcinoma	38	83	53.7(32-77)	70	6
Bouchekioua- Bouzaghrou K	2014	France	Breast cancer	94	60	56.87(27-87)	162	7
Bouchekioua- Bouzaghrou K	2014	France	Breast cancer	102	52	56.5 (27-87)	162	
Chen IC	2016	China	Breast cancer	161	408	48	120	6
Chen IC	2016	China	Breast cancer	88	189	54	120	
Chen IC	2016	UK and	Breast cancer	494	494	61.3	300	5

			Canada						
Chen IC	2016	UK and Canada	Breast cancer	488	487	62.6		300	
HamdyA.Azi m	2016	Egypt	Breast Cancer	12	20	51.3(25-82)		82.8	6
HamdyA.Azi m	2016	Egypt	Breast Cancer	11	21	51.3(25-82)		82.8	
Morton JP	2010	UK	Pancreatic cancer	20	86	NR		95	7
Yang JY	2015	China	Pancreatic ductal adenocarcinoma	36	169	NR		97	8
Li DZ	2018	China	Pancreatic neuroendocrine tumor	38	33	NR		190	8
Yang XW	2012	China	Gastric Cancer	76	24	65(31-85)		38	7
Huang Y	2014	China	Gastric carcinoma	24	91	61(37-80)		75	6
Ma LG	2016	China	Gastric Cancer	62	47	57(31-84)		99	8
Sun JJ	2016	China	Gastric Cancer	107	48	NR		70	6
Yin M	2017	China	Gastric Cancer	78	32	62(23-79)		72	7
Huang YH	2013	China	Hepatocellular carcinoma	31	39	57(43-72)		68	7
Lee SW	2015	China	Hepatocellular carcinoma	13	27	NR		101	7
Wu CC	2018	China	Hepatocellular carcinoma	41	52	NR		54	7

1									
2									
3									
4	Wang JH	2015	China	Intrahepatic	187	129	NR	99	8
5				cholangiocarcino					
6				ma					
7									
8									
9	Ma JJ	2014	China	Esophagus	73	47	NR	60	8
10				squamous					
11				cancer					
12									
13									
14									
15	He TY	2014	China	Colorectal cancer	63	95	NR	80.5	5
16									
17	Lu JL	2015	China	Prostate Cancer	78	31	NR	60	7
18									
19	Huang JH	2017	China	Glioma	92	88	50.8(10-86)	118	8
20									
21									
22	He SS	2017	China	Laryngeal	128	80	NR	212.2	8
23				squamous cell					
24				carcinoma					
25									
26									
27									
28									
29									
30									
31									
32									
33									
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									
48									
49									
50									
51									
52									
53									
54									
55									
56									
57									
58									
59									
60									

Table 2. LKB1 expression levels and survival.

Study	Assay method	Staining location	Cut-off value	Outcome	Analysis method	HR and 95%CI	
Ding XM	IHC	Both nucleus and cytoplasm	Lower than in normal airway epithelium	OS	UA	3.003(2.524-9.635)	
Tsai LH	IHC	No specific description	A score equal to or lower than 100	OS	UA	1.846(1.243-3.202)	
					MA	1.868(1.160-3.007)	
				RFS	UA	1.828(1.247-3.122)	
					MA	1.791(1.132-2.834)	
Yang LL	IHC	Cytoplasm	Score of 0-4	OS	UA	3.226(1.852-5.556)	
					MA	2.128(1.136-4.000)	
Calles A	IHC	Cytoplasm	No staining	OS	UA	1.44(0.92-2.28)	
ZhenZ	WB	Total protein	Bands of the breast cancer tissue in which the quantities were <0.5	OS	UA	3.754(1.899-10.75)	
					DFS	UA	2.529(1.383-5.933)
Bouchekioua-Bouzaghrou K	IHC	Cytoplasm	Staining intensity recorded as 0-1	OS	UA	0.418(0.181-0.708)	
					MA	0.403(0.199-0.820)	
					DFS	UA	0.495(0.249-0.809)
					MA	0.549(0.303-0.990)	
Bouchekioua-	IHC	nucleus	Staining intensity recorded as 0	OS	UA	1.417(0.722-2.704)	

1

2

3

4 Bouzaghrou K

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

DFS UA 1.279(0.732-2.225)

OS UA 1.2(0.67-2.15)

MA 0.766(0.453-1.296)

OS UA 0.98(0.6-1.61)

MA 1.054(0.665-1.671)

OS UA 1.6(0.9-1.25)

MA 0.937(0.772-1.138)

OS UA 1.09(0.91-1.3)

MA 1.024(0.839-1.250)

RFS UA 1.11(0.16-7.49)

MA 0.81(0.22-3.03)

RFS UA 5.22(0.23-118.46)

MA 0.36(0.15-0.10)

OS UA 1.877(1.280-4.318)

MA 1.87(1.09-3.22)

OS UA 2.278(1.495-3.472)

MA 1.845(1.189-2.865)

OS UA 5.31(0.2-144.02)

1							
2							
3			of the cells and/or weak staining				
4							
5							
6					DFS	UA	2.19(0.41-11.7)
7							
8							
9							
10	Yang XW	IHC	Both nucleus and cytoplasm	Staining intensity in the neoplasm less than that in normal mucosa	OS	UA	2.558(1.674-4.588)
11							
12							
13							
14							
15							
16	Huang Y	IHC	Both nucleus and cytoplasm	Staining intensity recorded as 0-1	OS	UA	2.514(1.026-4.092)
17							
18							
19							
20							
21							
22							
23	Ma LG	IHC	Both nucleus and cytoplasm	Scores ≤ 1	OS	UA	2.31(1.25-4.28)
24							
25							
26						MA	3.527(1.491-10.630)
27							
28							
29	Sun JJ	IHC	Both nucleus and cytoplasm	Scores of 0 and 1+ indicate negative result	OS	UA	1.45(0.54-3.91)
30							
31							
32							
33						MA	4.431 (1.363-14.407)
34							
35	Lin M	IHC	Both nucleus and cytoplasm	Staining intensity recorded as 0-1	OS	UA	1.07 (0.46-2.46)
36							
37							
38							
39	Huang YH	IHC	Cytoplasm	Staining index score ≤ 3	OS	UA	3.155(1.603-6.211)
40							
41						MA	2.179(1.066-4.444)
42							
43							
44					DFS	UA	2.737(1.629-6.271)
45							
46	Lee SW	IHC	Both nucleus and cytoplasm	H-score was lower than the median	OS	UA	0.517(0.284-0.931)
47							
48							
49							
50						MA	0.333(0.193-0.564)
51							
52	Wu CC	IHC	No specific description	Histoscore was ≤ 150	OS	UA	3.13(0.91-10.84)
53							
54							
55							
56							
57							
58							
59							
60							

1							
2							
3						MA	4.26(1.87-9.69)
4							
5							
6					RFS	UA	2.02(0.87-4.72)
7							
8						MA	2.05(1.11-3.81)
9							
10	Wang JH	IHC	Cytoplasm	Staining density lower than the	OS	UA	1.857(1.498–2.483)
11				median value			
12							
13							
14						MA	1.824(1.404–2.377)
15							
16	Ma JJ	IHC	Both nucleus and	Score of 0–4	OS	UA	0.57(0.33-0.97)
17			cytoplasm				
18							
19							
20	He TY	IHC	No specific	Score equal to or lower than 100	OS	UA	2.364(1.576-4.112)
21			description				
22							
23							
24						MA	3.146(1.876-5.276)
25							
26					RFS	UA	2.522(1.701-4.445)
27							
28							
29						MA	3.093(1.843-5.191)
30							
31	Lu JL	IHC	No specific	Staining of fewer than 20% of the	OS	UA	6.31(0.42-94.67)
32			description	tissue cells or no staining			
33							
34							
35						MA	3.981 (1.698–9.336)
36							
37	Huang JH	IHC	No specific	Percentage of positive cells \leq	OS	UA	2.02(1.07-3.83)
38			description	35%and/or staining intensity score			
39				of 0-1.			
40							
41							
42						MA	3.022(1.002-6.016)
43							
44							
45	He SS	IHC	Nucleus	Score \leq 4	OS	UA	1.17(0.72-1.9)
46							
47						MA	1.628(1.060–2.500)
48							
49							
50							
51							
52							
53							
54							
55							
56							
57							
58							
59							
60							

For peer review only

Table 3. LKB1 expression and clinicopathological characteristics.

Study	LKB1 expression	Age		Sex		Tumor differentiation		Tumor size		Lymph node metastasis		TNM stage
		≥60	<60	Male	Female	Poor	Well	T3-	T1-	Yes	No	III-IV

						T4		T2				
Huang YH	Low	26	5	23	8	15	16			19	12	
	High	31	8	17	22	20	19			27	12	
He TY	Low											
	High											
Bouchekio ua-Bouzag hou K	Low (cytoplasmic staining)			69	25	26	68	50	44			
	High			54	6	18	42	38	22			
	Low(nuclear staining)			83	19	34	68	63	39			
	High			40	12	10	42	25	27			
ShenZ	Low			35	3	13	25					
	High			69	14	11	73					
Tsai LH	Low	25	19			9	35	35	9	28	16	
	High	41	30			9	62	31	40	24	47	
Jiang LL	Low	16	17	17	16	23	10		18	15	12	21
	High	49	60	65	44	34	75		44	65	23	86
Yang JY	Low	16	20	32	4	35	1	17	19	16	20	
	High	101	68	159	10	132	37	45	124	31	138	
Calles A	Low	14	28									
	High	25	59									
Wang JH	Low	122	65	162	25	112	100	76	111	117	70	

1													
2													
3		High		93	46	90	49	63	51	42	97	56	83
4													
5	Morton JP	Low											
6													
7		High											
8													
9													
10	Ding XM	Low	12	12	13	11		9	15	3	21	22	2
11													
12		High	21	17	14	24		7	31	8	20	15	23
13													
14													
15	Yang XW	Low	52	24	60	16	62	14	57	19	59	17	48
16													
17		High	16	8	20	4	20	4	13	11	7	17	6
18													
19	Wu CC	Low	17	24	32	9						26	15
20													
21		High	25	27	45	7						32	20
22													
23													
24	Yin M	Low	43	35	54	24	57	21	71	7	56	22	68
25													
26		High	19	13	23	9	12	20	24	8	11	21	12
27													
28													
29	Huang Y	Low	51	17					65	26	64	27	80
30													
31		High	40	7					16	8	8	16	10
32													
33	Ma LG	Low	51	22	60	13	60	13	48	25	24	49	31
34													
35		high	36	11	36	11	24	23	24	23	5	42	6
36													
37													
38	Chen IC	low					126	25	16	145	67	91	23
39													
40		High					311	81	34	372	152	253	57
41													
42		Low					83	2	6	82	56	32	36
43													
44		High					177	12	15	174	106	83	66
45													
46		Low					457	37	20	474	241	253	85
47													
48		High					459	35	26	468	235	259	88
49													
50		Low					392	49	29	451	241	238	88
51													
52		High					398	46	24	446	213	260	85
53													
54													
55													
56													
57													
58													
59													
60													

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Li DZ	Low			26	12	6	32							
	High			16	17	1	32							
Huang YH	Low			56	36			52	40			77	15	
	High			54	34			20	68			43	55	
HamdyA. Azim	Low													
	High													
Lu JL	Low											47	31	
	High											11	20	
He SS	Low													
	High													
Ma JJ	Low	29	33	40	22	27	35	44	18	51	11	28	34	
	High	30	17	31	16	19	28	18	29	29	18	9	38	
Lee SW	Low													
	High													
Sun JJ	Low	60	47	79	28	78	29	73	34	60	47	55	52	
	High	28	20	42	6	38	10	22	26	16	32	8	40	

Table 4. Subgroup analyses of the association between LKB1 expression and OS after stratification by statistical analysis method, LKB1 assay method, country, cancer type, and intracellular staining location.

Stratification criterion	Value	HR(95%CI)	P value	Heterogeneity	
				I^2	P value
Analysis method	Univariate	1.61(1.36-1.92)	<0.001	76%	<0.001
	Multivariate	1.61(1.26-2.06)	<0.001	81%	<0.001
Assay method	IHC	1.58(1.33-1.89)	<0.001	77%	<0.001
	The others				
Country	Asian	1.71(1.42-2.07)	<0.001	78%	<0.001
	Not Asian	1.15(0.63-2.08)	0.65	75%	0.007
Cancer type	Lung	2.07(1.60-2.69)	<0.001	53%	0.09
	Breast	1.26(1.15-1.37)	<0.001	79%	<0.001
	Gastric	2.19(1.60-3.01)	<0.001	10%	0.34
	Pancreatic	2.16(1.53-3.05)	<0.001	0%	0.76
	Hepatocellular carcinoma	1.27(0.84-1.94)	0.26	89%	<0.001
	The others	1.63(1.35-1.96)	<0.001	79%	<0.001
Staining position	Both nucleus and cytoplasm	1.69(1.33-2.16)	<0.001	76%	<0.001
	Cytoplasm	1.78(1.49-2.13)	<0.001	77%	<0.001

Nucleus	1.25(0.85-1.85)	0.26	0%	0.65
Other	1.36(1.25-1.47)	<0.001	75%	<0.001

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of study inclusion and meta-analysis.




Figure 2A. Forest plot of OS by univariate analysis.

330x197mm (72 x 72 DPI)




Figure 2B. Forest plot of OS by multivariate analysis.

330x146mm (72 x 72 DPI)




Figure 2C. Forest plot of RFS by univariate analysis.

302x73mm (72 x 72 DPI)




Figure 2D. Forest plot of RFS by multivariate analysis.

302x73mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2E.Forest plot of DFS by univariate analysis.

330x67mm (72 x 72 DPI)




Figure 3A. Meta-analysis of the relationship between low LKB1 expression and tumor differentiation.

335x135mm (72 x 72 DPI)




Figure3B.Meta-analysis of the relationship between low LKB1 expression and tumor size.

335x146mm (72 x 72 DPI)




Figure 3C. Meta-analysis of the relationship between low LKB1 expression and lymph node metastasis.

329x135mm (72 x 72 DPI)




Figure 3D. Meta-analysis of the relationship between low LKB1 expression and TNM stage.

302x146mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure4. Funnel plot of OS by univariate analysis.

211x141mm (72 x 72 DPI)



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a meta-analysis.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n/a
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	5-6



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Association between LKB1 expression and prognosis of patients with solid tumors: an updated systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027185.R1
Article Type:	Research
Date Submitted by the Author:	27-Mar-2019
Complete List of Authors:	Ren, Yun; Guangxi Cancer Hospital and Guangxi Medical University Affiliated Cancer Hospital, hepatological surgery department Zhao, Feng; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Mo, Han; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Jia, Rong; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Tang, Juan; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Zhao, Xin; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Wei, Jue; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department; Guangxi medical university Huo, Rong; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department Li, Qiu; Affiliated Tumor Hospital of Guangxi Medical University, Hepatobiliary Surgery Department You, Xue; Guangxi Cancer Hospital and Guangxi Medical University Affiliated Cancer Hospital, hepatological surgery department ; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Diagnostics
Keywords:	LKB1, STK11, liver kinase B1, prognosis

SCHOLARONE™
Manuscripts

1
2
3
4 **Association between LKB1 expression and prognosis of patients with solid tumors: an**
5
6 **updated systematic review and meta-analysis**
7

8 Yun-Hong Ren¹, Feng-Juan Zhao^{1,2}, Han-Yue Mo¹, Rong-Rong Jia¹, Juan Tang¹, Xin-Hua
9 Zhao¹, Jue-Ling Wei^{1,2}, Rong-Rui Huo¹, Qiu-Qin Li¹, Xue-Mei You¹
10
11

12 **Author affiliations**
13

- 14
15 1. Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical
16 University, Nanning, China
17
18 2. Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research
19 Center, Nanning, China
20
21
22
23
24

25 **Correspondence:**
26

27 Xue-Mei You, Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi
28 Medical University, He Di Rd #71, Nanning 530021, China
29

30 Email: you_xuemei77@163.com
31

32 Telephone: +86 771 533 0855
33

34 Fax: +86 771 531 2000
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 ***Strengths and limitations of this study***
8

- 9
- 10 ◆ This review included large sample size to reveal the relationship between the expression
11 of LKB1 and solid tumors.
12
 - 13 ◆ Subgroup analyses and sensitivity analyses were performed to confirm the findings.
14
 - 15 ◆ The cut-off value of LKB1 among the included studies were inconsistent.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives. Liver kinase B1 (LKB1) is considered a tumor suppressor that can control cell growth and metabolism. Whether LKB1 expression levels are related to clinicopathology and prognosis is controversial. This review aimed to quantitatively examine the latest evidence on this question.

Design. An updated systematic review and meta-analysis on the association between LKB1 expression and prognosis of patients with solid tumors were performed.

Data sources. Eligible studies were identified through literature searches from database establishment until June 15, 2018 in the following databases: Embase, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure and Wan Fang databases.

Eligibility criteria. The association between LKB1 expression and clinicopathological characteristics, overall survival (OS), disease-free survival (DFS), and relapse-free survival (RFS) of patients with solid tumors were reported. Sufficient data was available to calculate the odds ratio (OR) or hazard ratio (HR) and 95% confidence interval (CI).

Data extraction and synthesis. Relevant data were meta-analyzed for OS, DFS, RFS and various clinical parameters.

Results. The systematic review included 25 studies containing 6,012 patients with solid tumors. Compared to patients with high LKB1 expression, patients with low expression showed significantly shorter OS in univariate analysis (HR = 1.63, 95%CI 1.35-1.97, $P < 0.01$) and multivariate analysis (HR = 1.61, 95%CI 1.26-2.06, $P < 0.01$). In contrast, the two groups showed similar DFS in univariate analysis (HR = 1.49, 95%CI 0.73-3.01, $P = 0.27$) as well as similar RFS in univariate analysis (HR = 1.44, 95%CI 0.65-3.17, $P = 0.37$) and

1
2
3
4 multivariate analysis (HR = 1.02, 95%CI 0.42-2.47, $P = 0.97$). Patients with low LKB1
5
6 expression showed significantly worse tumor differentiation (OR = 1.71, 95%CI 1.14-2.55, P
7
8 < 0.01), larger tumors (OR = 1.68, 95%CI 1.24-2.27, $P < 0.01$), earlier lymph node
9
10 metastasis (OR = 1.43, 95%CI 1.26-1.62, $P < 0.01$) and more advanced TNM stage (OR =
11
12 1.80, 95%CI 1.56-2.07, $P < 0.01$).
13
14
15

16
17 **Conclusion.** Low LKB1 expression predicts shorter OS, worse tumor differentiation, larger
18
19 tumors, earlier lymph node metastasis and more advanced TNM stage. Low LKB1 expression
20
21 may be a useful biomarker of poor clinicopathology and prognosis.
22
23

24
25 **Patient and public involvement statement.** This systematic review does not need ethical
26
27 approval. Results will be disseminated through conference presentations and publication in a
28
29 peer-reviewed, scientific journal.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The serine/threonine kinase liver kinase B1 (LKB1), also known as STK11, was originally observed to be mutated in the genes of patients with Peutz-Jeghers syndrome ¹. LKB1 is often mutated in lung, breast, gastric and other cancers ²⁻⁴. LKB1 plays roles in multiple cellular processes, including cell structure control, cell cycle regulation, apoptosis and cellular metabolism⁵⁻⁷. LKB1 phosphorylates multiple substrates, including AMPK, to act as a tumor suppressor to restrict tumorigenesis and metastasis ⁸. Mice with a Treg-specific deletion of LKB1 develop a fatal inflammatory disease, and LKB1 in Treg cells acts not through signalling by AMPK or the mammalian target of rapamycin complex1 (mTORC1) and Hif-1, but through signalling involving pd-1 and TNF receptor proteins ⁹. LKB1 deficiency can render tumor cells sensitive to metabolic stress, which may turn out to be an anti-tumor strategy ¹⁰.

Although several studies have examined the role of LKB1 in tumor inhibition, its role in the prognosis of solid tumors has not been conclusively determined. Several studies suggest that decreased LKB1 expression indicates poor prognosis. In fact, meta-analysis showed that decreased LKB1 expression in patients with solid tumors may be related to poor prognosis and serve as a predictor of clinicopathological prognostic factors ¹¹. However, other studies have not reproduced these findings, and some have even suggested that decreased LKB1 may correlate with favorable survival.

Therefore we systematically reviewed and meta-analyzed the relevant literature to understand

1
2
3
4 the current evidence about a relationship between LKB1 expression and prognosis in patients
5
6 with solid tumors.
7
8
9

11 **Materials and Methods**

13 *Literature search strategy*

14
15
16
17 The following databases were searched from database establishment to June 15, 2018 to
18
19 identify studies of LKB1 expression and survival in solid tumors: PubMed, Embase, Web of
20
21 Science, Cochrane Database, the Chinese National Knowledge Infrastructure, and Wang
22
23 Fang. Searches were carried out using terms such as LKB1, STK11, liver kinase B1,
24
25 prognosis, prognostic, survival, and overall survival. For example, we searched PubMed
26
27 using the following strategy: (LKB1[tw] OR STK11[tw] OR "liver kinase B1"[tw] OR
28
29 "serine-threonine kinase 11"[tw]) AND ("prognosis"[MeSH Terms] OR prognoses[tw] OR
30
31 prognostic[tw] OR "prognostic factor"[tw] OR "prognostic factors"[tw] OR factor[tw] OR
32
33 factors[tw] OR outcome[tw] OR survival[tw] OR metastases[tw] OR metastasis[tw] OR
34
35 migration[tw] OR transplantation[tw] OR transfer[tw] OR shift[tw] OR divert[tw] OR
36
37 recurrence[tw] OR relapse[tw] OR reappear[tw] OR recur[tw] OR recidivation[tw] OR
38
39 invasion[tw]).
40
41
42
43
44
45
46
47
48
49

51 *Study inclusion and exclusion criteria*

52
53 Studies were considered eligible if they met the following criteria:(1) LKB1expression in
54
55 cancer tissue (obtained via surgery or biopsy) was measured by immunohistochemistry or
56
57 Western blotting; (2)the association was studied between LKB1 expression and
58
59
60

1
2
3
4 clinicopathological characteristics, overall survival (OS), disease-free survival (DFS), or
5
6 recurrence-free survival (RFS) of patients with solid tumors; (3) sufficient data were
7
8 published for calculating an odds ratio (OR) or hazard ratio (HR) and 95% confidence
9
10 interval (CI); and (4) the study was published as a full-text article in English or Chinese. If
11
12 we retrieved multiple studies conducted by the same research group and involving
13
14 overlapping patient populations, only the most recent or most complete study was included in
15
16 the meta-analysis. Articles were excluded if they (1) were duplicate publications; (2) were
17
18 case reports, reviews, letters or animal studies; or (3) did not report survival outcomes.
19
20
21
22
23
24
25
26

27 *Study quality assessment*

28
29 Two reviewers independently assessed the quality of included studies using the standard
30
31 Newcastle–Ottawa scale (NOS) from 0 to 9. NOS scores of 9-7 were defined as high quality,
32
33 6-4 as intermediate quality, and 3-1 as low quality.
34
35
36
37
38
39

40 *Data extraction*

41
42 Two researchers (YHR and FJZ) independently screened all titles and abstracts identified in
43
44 the initial search. Articles remaining after this screen were read in full and assessed for
45
46 eligibility. The following types of data were extracted: (1) name of first author, publication
47
48 year, country, type of cancer and number of patients; (2) patient age, gender, follow-up time,
49
50 type of LKB1 assay, intracellular location where LKB1 staining was examined, LKB1 cut-off
51
52 value for classifying expression as high or low, survival data (OS, DFS, RFS), statistical
53
54 method used to analyze survival data; (3) tumor differentiation, tumor size, lymph node
55
56
57
58
59
60

1
2
3
4 metastasis and tumor stage. All data were cross-checked by two researchers, and
5
6 disagreements were resolved by a third reviewer (XMY). If study information was
7
8 incomplete or unclear, we contacted the corresponding author in an attempt to collect
9
10 accurate information.
11
12

13 14 15 16 17 *Statistical analysis*

18
19 Correlation between LKB1 expression and OS of patients with solid tumors was evaluated in
20
21 terms of HR and 95%CI. If a study showed Kaplan-Meier survival curves but not HRs with
22
23 95%CI, data were extracted from survival curves using Engauge Digitizer 4.1 and the
24
25 Tierney
26
27 table. Correlation between LKB1 expression and clinicopathological characteristics of
28
29 patients with solid tumors was evaluated in terms of OR and 95%CI.
30
31
32
33

34
35
36
37 HRs and ORs were meta-analyzed using the random-effects model in R software. *P* values
38
39 were two-sided and values < 0.05 were considered statistically significant.
40
41

42
43
44
45 *I*² was used to assess statistical heterogeneity. If *I*² > 50%, heterogeneity was considered to
46
47 exist among all included studies, and we conducted a subgroup analysis to investigate its
48
49 possible source. If *I*² < 50%, heterogeneity among all included studies was regarded as
50
51 insignificant, and data were directly pooled.
52
53
54

55
56
57
58 To assess the stability of our meta-analysis results, we conducted a sensitivity analysis to
59
60

1
2
3
4 testing the influences of individual studies on the pooled HR or *P* value for the remaining
5
6 studies. Potential for publication bias was assessed by examining funnel plots, Begg's and
7
8 Egger's test of survival data.
9

14 **Results**

15
16 A total of 4,858 potentially relevant studies were identified in literature searches, of which
17
18 3,374 were excluded as duplicate publications. After screening titles and abstracts, 50 studies
19
20 were read in full, leading to 25 that were included in the meta-analysis¹²⁻³⁶ (Fig 1). Data from
21
22 all 25 studies were meta-analyzed to examine the potential correlation of LKB1 expression
23
24 with clinicopathological characteristics. Data from 24 studies were meta-analyzed to examine
25
26 the potential correlation between LKB1 expression and OS. Data from five studies were used
27
28 to analyze the potential correlation between LKB1 expression and DFS. Four studies reported
29
30 the association of LKB1 expression with RFS.
31
32
33
34
35
36

37 *Description of studies*

38
39 The 25 studies in the systematic review involved 6,012 patients from six countries: China,
40
41 USA, France, UK, Canada, and Egypt. Data on OS were reported in 24 studies, data on RFS
42
43 in five studies, and data on DFS in four studies. Patients covered a range of cancers,
44
45 including cancers of the lung, breast, prostate or pancreas; gastric cancer; hepatocellular
46
47 carcinoma; esophagus squamous cancer; colorectal cancer; glioma; and laryngeal squamous
48
49 cell carcinoma. Tables 1-2 summarize the characteristics of the included studies. Supplement
50
51 table 1 lists clinicopathological characteristics and LKB1 expression. Eight studies had an
52
53 NOS score of 8; 11 studies, 7; 6 studies, 6; and 3 studies, 5 (supplement table 2 and
54
55
56
57
58
59
60

1
2
3
4 supplement table 3).
5
6
7
8

9 Of the 25 studies, 16 reported HRs from multivariate analysis, which we used directly. For
10 the nine remaining studies, we estimated HRs for OS, DFS, and RFS from survival curves
11 and Tierney's table.
12
13
14
15
16

17 18 19 *Association between LKB1 expression and OS*

20
21
22 Given heterogeneity among the studies ($I^2 = 74.0\%$, $P < 0.001$), a random-effects model was
23 used to meta-analyze the data. The pooled HR describing OS for patients with low LKB1
24 expression relative to OS for patients with high expression is shown in Fig 2. Decreased
25 LKB1 expression was significantly associated with OS: low expression was associated with
26 significantly higher risk of poor survival (HR = 1.63, 95%CI 1.35-1.97, $P < 0.01$).
27
28
29
30
31
32
33
34
35
36

37 To assess the predictive role of decreased LKB1, subgroup analysis was performed after
38 stratifying the results based on multivariate analysis, type of LKB1 assay, country, cancer
39 type, and intracellular location of LKB1 staining that was examined. Subgroup analysis based
40 on multivariate analysis showed that decreased LKB1 expression was related to poor OS in
41 Table 3 (HR = 1.61, 95%CI 1.26-2.06, $P < 0.001$ with significant heterogeneity). This
42 relationship was observed for the following cancer types: lung cancer (HR = 2.07, 95%CI
43 1.60-2.69, $P < 0.01$, $I^2 = 0\%$), pancreatic cancer (HR = 2.16, 95%CI 1.53-3.05, $P < 0.001$, I^2
44 = 0%), gastric cancer (HR = 2.11, 95%CI 1.60-3.01, $P < 0.01$, $I^2 = 0\%$), and breast cancer (HR
45 = 1.26, 95%CI 1.15-1.37, $P < 0.01$). However, this relationship was not observed in the case
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 of hepatocellular carcinoma (HR = 1.27, 95%CI 0.84-1.94, $P = 0.26$ with significant
5
6 heterogeneity).

7
8
9
10
11 Among Asian patients, decreased LKB1 expression was associated with significantly shorter
12
13 OS (HR = 1.70, 95%CI 1.42-2.05, $P < 0.01$); this relationship was not observed among
14
15 non-Asian patients (HR = 1.15, 95%CI 0.63-2.08, $P = 0.65$). When the subgroup according to
16
17 (Table 3).
18
19
20
21
22
23

24
25 Pooled HR for the subgroup of patients tested by anti-LKB1 immunohistochemistry was 1.58
26
27 (95%CI 1.33–1.88, $P < 0.01$). Low LKB1 expression based on cytoplasmic staining predicted
28
29 significant adverse prognosis (HR = 1.78, 95%CI 1.49-2.13, $P < 0.01$). This relationship was
30
31 not observed when the judgment of low LKB1 expression was based on nuclear staining (HR
32
33 = 1.25, 95%CI 0.85-1.85, $P = 0.26$, $I^2 = 0\%$) (Table 3).
34
35
36
37
38
39
40

41 Details of the subgroup analysis are listed in Table 3. The results of the sensitivity analysis
42
43 showed that the exclusion of each single study did not alter the results significantly (Fig 3).
44

45 These results suggest that our meta-analysis gave credible results.
46
47
48
49

50 *Association of LKB1 expression with DFS and RFS*

51
52
53 Studies showed significant heterogeneity, so data were meta-analyzed using a random-effect
54
55 model. Low LKB1 expression did not show a significant association with RFS based on
56
57 univariate analysis (HR = 1.44, 95%CI 0.65-3.17, $P = 0.37$) or multivariate analysis (HR =
58
59
60

1
2
3
4 1.02, 95%CI 0.42-2.47, $P = 0.97$). Similarly, no significant correlation was observed between
5
6 LKB1 expression and DFS based on univariate analysis and random-effect meta-analysis
7
8 (HR = 1.49, 95%CI 0.73-3.01, $P = 0.27$) (Table 4).
9
10

11 12 13 14 *Association between LKB1 expression and clinicopathological characteristics*

15
16
17 Meta-analysis of the relationship between LKB1 expression and clinicopathological
18
19 characteristics (Table 5) failed to show a significant association of decreased LKB1
20
21 expression with age (OR = 0.78, 95%CI 0.57-1.05, $P = 0.10$) or sex (OR = 0.97, 95%CI
22
23 0.78-1.19, $P = 0.76$). In contrast, low LKB1 expression was significantly related to worse
24
25 differentiation (OR = 1.17, 95%CI 1.14-2.55, $P < 0.01$), deeper invasion (OR = 1.68, 95%CI
26
27 1.24-2.27, $P < 0.01$), earlier lymph node metastasis (OR = 1.43, 95%CI 1.26-1.62, $P < 0.01$),
28
29 and more advanced clinical stage (OR = 1.80, 95%CI 1.56-2.07, $P < 0.01$).
30
31
32
33

34
35 Results are shown as individual and pooled OR with 95% confidence intervals
36

37 38 *Publication bias*

39
40 Funnel plots of OS appeared asymmetric (Fig.4), suggesting the possibility of publication
41
42 bias among the included studies. However, findings with Begg's ($P = 0.5402$) and Egger's
43
44 tests ($P = 0.2414$) implied no publication bias.
45
46
47
48
49

50 51 **Discussion**

52
53 This meta-analysis suggests that among patients with many kinds of solid tumors, low LKB1
54
55 expression is associated with worse OS, whereas LKB1 expression does not appear to
56
57 significantly influence DFS or RFS. This suggests that low LKB1 expression may be a
58
59
60

1
2
3
4 predictor of unfavorable prognosis. In fact, the available evidence suggests an association of
5
6 low LKB1 expression with worse tumor differentiation, deeper invasion, more advanced
7
8 clinical stages, and earlier metastasis to lymph nodes and other organs. These findings are
9
10 consistent with previous conclusions ¹¹, and they were confirmed in our data set using
11
12 sensitivity analysis.
13
14
15
16
17
18

19 Some potentially interesting findings emerged from subgroup analyses conducted after
20
21 stratifying the data according to various criteria. Our meta-analysis linked low LKB1
22
23 expression with poor prognosis in Asians but not in non-Asians, which may reflect genetic
24
25 and environmental differences. While low LKB1 expression was associated with worse
26
27 prognosis in patients with certain types of cancer (lung, gastric, pancreatic, breast), this was
28
29 not the case in patients with hepatocellular carcinoma. This difference may relate to different
30
31 co-morbidities associated with the types of cancer. Lung cancer, stomach cancer, breast
32
33 cancer, and pancreatic cancer have high incidence rates around the world, and more studies
34
35 have been done. The association between low expression of LKB1 and poor prognosis was
36
37 observed when low expression was based on cytoplasmic staining, but not when it was based
38
39 on nuclear staining. The reason may be that the regulation of mTORC1 by LKB1 and AMPK
40
41 occurs on the exterior of RAB7/LAMP1-positive lysosomal membranes ³⁷. In this regulation,
42
43 LKB1 phosphorylates and activates cell energy-sensing AMPK, which in turn negatively
44
45 affects TORC1, which is important for controlling energy metabolism, cell survival and cell
46
47 growth under conditions of metabolic stress, such as nutrient deficiency. Further studies are
48
49 needed to elucidate the mechanism of action of LKB1.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Our meta-analysis suggests that at least in many types of solid tumors, LKB1 acts as a tumor
8
9 suppressor. This is consistent with several studies in the literature. For example, a decrease in
10
11 LKB1 expression as a result of HBx-mediated p53 inactivation may be responsible for colony
12
13 formation and invasiveness in hepatocellular carcinoma ²⁹. LKB1 deficiency in some tumors
14
15 may be associated with up-regulation of glutamate dehydrogenase 1, which activates
16
17 CamKK2 and its downstream effector AMPK to increase metastatic potential ³⁸. LKB1 loss
18
19 may drive ovarian serous tumorigenesis by disrupting apical-basal polarity in the presence of
20
21 mutated p53 in fallopian tube cells ³⁹. On the one hand, several studies have suggested an
22
23 oncogenic role for LKB1 and AMPK under certain conditions ⁴⁰, such as when class III
24
25 phosphatidylinositol-3-OH kinase is inactivated ⁴¹. Further work is needed to clarify under
26
27 what conditions LKB1 acts as a tumorigenic or tumor-suppressing molecule.
28
29
30
31
32
33
34
35
36
37

38 The results of our meta-analysis should be interpreted with caution given several limitations.
39
40 First, we had to assess OS, DFS and/or RFS from Kaplan-Meier survival curves in several
41
42 studies, such that HRs and 95% CIs were estimated indirectly. Second, studies showed
43
44 substantial heterogeneity for outcomes, although we did attempt to minimize the effects of
45
46 such heterogeneity by using a random-effect meta-analysis model, performing subgroup
47
48 analyses and checking results through sensitivity analysis. Third, there is no consensus on
49
50 LKB1 cut-off values for defining expression as low or high, which may influence conclusions
51
52 about correlations and their clinical significance. Fourth, the funnel plots suggest the potential
53
54 for publication bias. This may reflect the generally observed bias toward publication of
55
56
57
58
59
60

1
2
3
4 positive findings. Fifth, our meta-analysis did not account for numerous other factors that
5
6 may also affect prognosis, such as co-morbidities and treatment history. In most cases, this
7
8 information was not reported in the included studies.
9
10

11
12
13
14 Our results justify the design of rigorous in vitro and animal studies designed to explore how
15
16 LKB1 influences the prognosis of various types of solid cancers. Ultimately this work should
17
18 be extended through human studies, preferentially randomized controlled trials.
19
20
21
22

23 24 **Conclusions**

25
26
27 The available evidence links low LKB1 expression with poor prognosis in patients with
28
29 various types of solid tumors. This suggests that LKB1 may be a biomarker for various
30
31 cancers. These findings should be verified and extended in human studies, and the
32
33 mechanisms underlying the association of LKB1 expression and prognosis should be
34
35 explored.
36
37
38

39
40 **Contributors:** XMY and HYM designed the study. FJZ, HYM and RRJ conduct systematic
41
42 search, search literature and extract data. YHR analyzed the data. YHR and FJZ wrote the
43
44 first draft of the article. JT, XHZ, JLW, QQL and RRH contributed significant knowledge
45
46 content and critical expertise and revisions to the manuscript
47

48 **Funding:** This work was supported by the Graduate Course Construction Project of Guangxi
49
50 Medical University (YJSA2017014), the Foundation Ability Enhancement Project for Young
51
52 Teachers in Guangxi Universities (2018KY0122, 2017KY0098), the Guangxi Natural
53
54 Science Foundation (2018GXNSFBA138018), the Research and Development Program of
55
56 Guangxi science and technology department(2017AB45190), the Research and Development
57
58 of Appropriate Medical and Health Technology Project in Guangxi (S201417-03), and
59
60 Guangxi Health and Family Planning Commission Chinese Medicine Science and

1
2
3
4 Technology Special Subject (GZLC16-36).

5 **Competing interests:** The authors have declared that no competing interests exist.

6
7 **Patient consent:** Not required.

8
9 **Provenance and peer review:** Not commissioned, externally peer reviewed.

10
11 **Data sharing statement:** No additional data are available.

12
13
14
15 Legends:

16
17 Fig 1. Flow diagram of the eligible studies

18
19 Fig 2. Forest plot of the association between decrease LKB1 expression and OS

20
21 Fig 3. Sensitivity analysis of OS in the meta-analysis

22
23 Fig 4. Funnel plot for the potential publication bias

References

1. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. *Cellular and molecular life sciences : CMLS*. May 1999;55(5):735-750.
2. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. *Nature*. Aug 16 2007;448(7155):807-810.
3. Zhuang ZG, Di GH, Shen ZZ, et al. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. *Molr Cancer Res: MCR*. Nov 2006;4(11):843-849.
4. Takahashi M, Sakayori M, Takahashi S, et al. A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer. *JGastroenterology*. 2004; 39(12): 1210-1214.
5. Amin N, Khan A, St. Johnston D, et al. LKB1 regulates polarity remodeling and adherens junction formation in the Drosophila eye. *Proc Natil Acad Sci*. 2009;106(22):8941-8946.
6. Granot Z, Swisa A, Magenheim J, et al. LKB1 Regulates Pancreatic β Cell Size, Polarity, and Function. *Cell Metab*. 2009;10(4):296-308.
7. Kullmann L, Krahn MP. Controlling the master—upstream regulation of the tumor suppressor LKB1. *Oncogene*. 2018;37(23):3045-57.
8. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer*. Aug 2009;9(8):563-575.
9. Yang K, Blanco DB, Neale G, et al. Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. *Nature*. 2017;548(7669):602-606.
10. Parker SJ, Svensson RU, Divakaruni AS, et al. LKB1 promotes metabolic flexibility in response to energy stress. *Metab Eng*. Sep 2017;43(Pt B):208-217.
11. Xiao J, Zou Y, Chen X, et al. The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis. *PloS one*. 2016;11(4):e0152674.
12. Ding XM, Li ZP, et al. Expression and clinical significance of LKB1 protein in lung adenocarcinoma tissues. *Chin J Cancer Prev T Rea T*, September 2005, 12(17):1281-1284.
13. Tsai LH, Chen PM, Cheng YW, et al. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas. *Oncogene*. Jul 17 2014;33(29):3851-3860.
14. Jiang L, Liang X, et al. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer. *Oncol Rep*. 2014;32(5):1931-1938.
15. Calles A, Sholl LM, Rodig SJ, et al. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. *Clini Cancer Res*. Jun 15 2015;21(12):2851-2860.
16. Shen Z, Wen XF, et al. The Tumor Suppressor Gene LKB1 Is Associated with Prognosis in Human Breast Carcinoma. *Clini Cancer Res*. 2002;8(7):2085-2090.
17. Bouchekioua-Bouzaghrou K, Poulard C, Rambaud J, et al. LKB1 when associated with methylatedERalpha is a marker of bad prognosis in breast cancer. *Int JCancer*. Sep 15 2014;135(6):1307-1318.
18. Chen IC, Chang YC, Lu YS, et al. Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. *Sci Rep*. Feb 15 2016;6:21374.
19. Azim HA, Kassem L, Treilleux I, et al. Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. *Transl Oncol*.

- 1
2
3
4 Apr 2016;9(2):114-123.
- 5 20. Morton JP, Jamieson NB, Karim SA, et al. LKB1 haploinsufficiency cooperates with Kras to promote
6 pancreatic cancer through suppression of p21-dependent growth arrest. *Gastroenterology*. Aug
7 2010;139(2):586-597, 597 e1-6.
- 8 21. Yang JY, Jiang SH, Liu DJ, et al. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal
9 Adenocarcinoma. *Sci Rep*. May 27 2015;5:10575.
- 10 22. Yang XW, Lin T, et al. Expression of LKB1 protein in gastric cancer tissue and its clinical significance.
11 *Chin Arch Gen Surg*. 2012; 6:51-56.
- 12 23. Li D, Zhou Y, Liu Y, et al. Decreased expression of LKB1 predicts poor prognosis in pancreatic
13 neuroendocrine tumor patients undergoing curative resection. *Oncol Targets Ther*.
14 2018;11:1259-1265.
- 15 24. Huang Y, Xia L, et al. Expression of LKB1 and vascular endothelial growth factor in gastric cancer tissue
16 and its clinical significance. *Pract Geriatr*. 2014;28(9):734-737.
- 17 25. Ma LG, Bian SB, Cui JX, et al. LKB1 inhibits the proliferation of gastric cancer cells by suppressing the
18 nuclear translocation of Yap and beta-catenin. *Int JMol Med*. Apr 2016;37(4):1039-1048.
- 19 26. Yin M, Bian SB, et al. Expression and clinical significance of LKB1 and ZEB1 in gastric cancer tissues.
20 *Guizhou Med*. 2017;41(10):1021-1024.
- 21 27. Huang YH, Chen ZK, Huang KT, et al. Decreased Expression of LKB1 Correlates with Poor Prognosis in
22 Hepatocellular Carcinoma Patients Undergoing Hepatectomy. *Asian Pac J Cancer Prev*.
23 2013;14(3):1985-1988.
- 24 28. Lee SW, Li CF, et al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell
25 survival under energy stress. *Mol Cell*, 2015; 57(6): 1022-33.
- 26 29. Wu CC, Wu DW, et al. Hepatitis B virus X protein represses LKB1 expression to promote tumor
27 progression and poor postoperative outcome in hepatocellular carcinoma. *Surgery*, 2018. 163(5): p.
28 1040-1046.
- 29 30. Wang J, Zhang K, et al. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt
30 signaling and malignant characteristics of human intrahepatic cholangiocarcinoma. *Oncotarget*, 2015.
31 6(22): p. 18906-18920.
- 32 31. Ma JJ, Du YM, et al. Expression and significance of LKB1 protein in esophageal squamous cell
33 carcinoma. *Medicine and Philosophy*, 2014. 35(2B): p. 65-68.
- 34 32. He TY, Tsai LH, et al. LKB1 loss at transcriptional level promotes tumor malignancy and poor patient
35 outcomes in colorectal cancer. *Ann Surg Oncol*, 2014. 21 Suppl 4: p. S703-710.
- 36 33. Lu J, Sun P, et al. Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients.
37 *Med Sci Monit*, 2015. (30)21: p. 3722-3727.
- 38 34. Huang J, Chen HW, et al. Downregulation of LKB1 promotes tumor progression and predicts
39 unfavorable prognosis in patients with glioma. *Oncol Lett*, 2017. 13(3): p. 1688-1694.
- 40 35. He SS, Chen Y, et al. Loss of LKB1 Expression Decreases the Survival and Promotes Laryngeal Cancer
41 Metastasis. *J Cancer*, 2017. 8(17): p. 3548-3554.
- 42 36. Sun J, Ling B, et al. Decreased Expression of Tumor-suppressor Gene LKB1 Correlates with Poor
43 Prognosis in Human Gastric Cancer. *Anticancer Res*, 2016. 36(3): p. 869-876.
- 44 37. Zhang CS, Jiang B, Li M, et al. The lysosomal v-ATPase-Ragulator complex is a common activator for
45 AMPK and mTORC1, acting as a switch between catabolism and anabolism. *Cell Metab*. Sep 2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 2014;20(3):526-540.
- 4 38. Jin L, Chun J, Pan C, et al. The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis
5 through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. *Mol cell*. 2018;69(1):87-99.e87
6
- 7 39. George SH, Milea A, Sowamber R, Chehade R, Tone A, Shaw PA. Loss of LKB1 and p53 synergizes to
8 alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. *Oncogene*. Jan 7
9 2016;35(1):59-68.
10
- 11 40. Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link - ten years after. *BMC biology*.
12 Apr 15 2013;11:36.
13
- 14 41. O'Farrell F, Lobert VH, Sneeggen M, et al. Class III phosphatidylinositol-3-OH kinase controls epithelial
15 integrity through endosomal LKB1 regulation. *Nature cell biology*. Dec 2017;19(12):1412-1423.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Main characteristics of included studies and Newcastle-Ottawa scale scores.

Study	Year	Country	Type of cancer	No. cases		Age in year, median(range)	Follow-up, mo.	NOS score
				Low	High			
				LKB1	LKB1			
Ding XM	2005	China	Lung adenocarcinoma	24	38	60.5(32-77)	80	7
Tsai LH	2013	China	Lung adenocarcinomas	44	71	NR	140	7
Jiang LL	2014	China	Non-small cell lung cancer	33	109	58.2(31-84)	71	7
Calles A	2015	USA	Lung adenocarcinoma	42	84	63.5(30-84)	60	7
Shen Z	2002	China	Breast carcinoma	38	83	53.7(32-77)	70	6
Bouchekioua- Bouzaghrou K	2014	France	Breast cancer	94	60	56.87(27-87)	162	7
Bouchekioua- Bouzaghrou K	2014	France	Breast cancer	102	52	56.5 (27-87)	162	
Chen IC	2016	China	Breast cancer	161	408	48	120	6
Chen IC	2016	China	Breast cancer	88	189	54	120	
Chen IC	2016	UK and Canada	Breast cancer	494	494	61.3	300	5
Chen IC	2016	UK and Canada	Breast cancer	488	487	62.6	300	
HamdyA.Azi m	2016	Egypt	Breast Cancer	12	20	51.3(25-82)	82.8	6
HamdyA.Azi m	2016	Egypt	Breast Cancer	11	21	51.3(25-82)	82.8	
Morton JP	2010	UK	Pancreatic cancer	20	86	NR	95	7
Yang JY	2015	China	Pancreatic ductal adenocarcinoma	36	169	NR	97	8

1									
2									
3	Li DZ	2018	China	Pancreatic	38	33	NR	190	8
4				neuroendocrine					
5				tumor					
6									
7									
8	Yang XW	2012	China	Gastric Cancer	76	24	65(31-85)	38	7
9	Huang Y	2014	China	Gastric	24	91	61(37-80)	75	6
10				carcinoma					
11									
12	Ma LG	2016	China	Gastric Cancer	62	47	57(31-84)	99	8
13									
14	Sun JJ	2016	China	Gastric Cancer	107	48	NR	70	6
15	Yin M	2017	China	Gastric Cancer	78	32	62(23-79)	72	7
16									
17	Huang YH	2013	China	Hepatocellular	31	39	57(43-72)	68	7
18				carcinoma					
19									
20	Lee SW	2015	China	Hepatocellular	13	27	NR	101	7
21				carcinoma					
22									
23	Wu CC	2018	China	Hepatocellular	41	52	NR	54	7
24				carcinoma					
25									
26	Wang JH	2015	China	Intrahepatic	187	129	NR	99	8
27				cholangiocarcino					
28				ma					
29									
30	Ma JJ	2014	China	Esophagus	73	47	NR	60	8
31				squamous					
32				cancer					
33									
34									
35	He TY	2014	China	Colorectal cancer	63	95	NR	80.5	5
36	Lu JL	2015	China	Prostate Cancer	78	31	NR	60	7
37									
38	Huang JH	2017	China	Glioma	92	88	50.8(10-86)	118	8
39	He SS	2017	China	Laryngeal	128	80	NR	212.2	8
40				squamous cell					
41				carcinoma					
42									
43									

44 NR: No resources

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Table 2.** LKB1 expression levels and survival.

Study	Assay method	Staining location	Cut-off value	Outcome	Analysis method	HR and 95%CI
Ding XM	IHC	Both nucleus and cytoplasm	Lower than in normal airway epithelium	OS	UA	3.003(1.524-5.865)
Isai LH	IHC	No specific description	A score equal to or lower than 100	OS	UA	1.846(1.147-2.952)
					MA	1.868(1.160-3.007)
				RFS	UA	1.828(1.247-3.122)
					MA	1.791(1.132-2.834)
Jiang LL	IHC	Cytoplasm	Score of 0-4	OS	UA	3.226(1.856-5.586)
					MA	2.128(1.136-4.000)
Galles A	IHC	Cytoplasm	No staining	OS	UA	1.440(0.910-2.270)
Shen Z	WB	Total protein	Bands of the breast cancer tissue in which the quantities were <0.5	OS	UA	3.754(1.583-8.932)
				DFS	UA	2.529(1.383-5.933)
Bouchekioua-Beuzaghou K	IHC	Cytoplasm	Staining intensity recorded as 0-1	OS	UA	0.418(0.211-0.828)
					MA	0.403(0.199-0.820)
				DFS	UA	0.495(0.249-0.809)
					MA	0.549(0.303-0.990)
Bouchekioua-Beuzaghou K	IHC	nucleus	Staining intensity recorded as 0	OS	UA	1.417(0.722-2.734)
				DFS	UA	1.278(0.732-2.225)
Chen IC	IHC	No specific description	A score of 0 or 1	OS	UA	1.200(0.670-2.150)
					MA	0.766(0.453-1.296)
Chen IC	IHC	No specific description	A score of 0 or 1	OS	UA	0.980(0.600-1.610)
					MA	1.054(0.665-1.671)
Chen IC	microarray data	No specific description	Lower than the median expression level	OS	UA	1.600(1.360-1.894)
					MA	0.937(0.772-1.138)
Chen IC	microarray data	No specific description	Lower than the median expression level	OS	UA	1.090(0.910-1.300)
					MA	1.024(0.839-1.250)

1							
2							
3	Hamdy A. Azim	IHC	Cytoplasm	Staining intensity recorded as 0	RFS	UA	1.110(0.160-7.490)
4						MA	0.810(0.220-3.030)
5							
6	Hamdy A. Azim	IHC	Nucleus	Staining intensity recorded as 0	RFS	UA	5.220(0.23-118.460)
7						MA	0.360(0.150-0.100)
8							
9	Morton JP	IHC	Cytoplasm	Histoscore was ≤ 100	OS	UA	1.877(1.020-3.448)
10						MA	1.870(1.090-3.220)
11							
12	Yang JY	IHC	No specific description	A total score < 4	OS	UA	2.278(1.495-3.472)
13						MA	1.845(1.189-2.856)
14							
15							
16	Li DZ	IHC	Cytoplasm	Strong immunostaining in $\leq 50\%$ of the cells and/or weak staining	OS	UA	5.310(0.200-142.482)
17					DFS	UA	2.190(0.410-11.700)
18							
19							
20							
21							
22							
23	Yang XW	IHC	Both nucleus and cytoplasm	Staining intensity in the neoplasm less than that in normal mucosa	OS	UA	2.558(1.554-4.233)
24							
25							
26							
27	Huang Y	IHC	Both nucleus and cytoplasm	Staining intensity recorded as 0-1	OS	UA	2.514(1.260-5.022)
28							
29							
30							
31							
32	Ma LG	IHC	Both nucleus and cytoplasm	Scores ≤ 1	OS	UA	2.310(1.250-4.270)
33							
34							
35						MA	3.527(1.491-10.630)
36	Sun JJ	IHC	Both nucleus and cytoplasm	Scores of 0 and 1+ indicate negative result	OS	UA	1.450(0.540-3.900)
37							
38							
39						MA	4.431(1.363-14.407)
40							
41	Yin M	IHC	Both nucleus and cytoplasm	Staining intensity recorded as 0-1	OS	UA	1.070(0.460-2.470)
42							
43							
44	Liang YH	IHC	Cytoplasm	Staining index score ≤ 3	OS	UA	3.155(1.603-6.211)
45						MA	2.179(1.066-4.44)
46							
47					DFS	UA	2.737(1.629-6.271)
48							
49	Lee SW	IHC	Both nucleus and cytoplasm	H-score was lower than the median	OS	UA	0.517(0.284-0.931)
50							
51						MA	0.333(0.193-0.564)
52							
53	Wu CC	IHC	No specific description	Histoscore was ≤ 150	OS	UA	3.130(0.910-10.840)
54							
55						MA	4.260(1.870-9.690)
56							
57					RFS	UA	2.020(0.870-4.720)
58							
59						MA	2.050(1.110-3.810)
60							

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Wang JH	IHC	Cytoplasm	Staining density lower than the median value	OS	UA	1.857(1.438–2.386)
					MA	1.824(1.404–2.377)
Ma JJ	IHC	Both nucleus and cytoplasm	Score of 0–4	OS	UA	0.570(0.330-0.980)
He TY	IHC	No specific description	Score equal to or lower than 100	OS	UA	2.364(1.466-3.812)
					MA	3.146(1.876-5.276)
				RFS	UA	2.522(1.701-4.445)
					MA	3.093(1.843-5.191)
Lu JL	IHC	No specific description	Staining of fewer than 20% of the tissue cells or no staining	OS	UA	6.310(0.420-94.730)
					MA	3.981(1.698–9.336)
Wang JH	IHC	No specific description	Percentage of positive cells \leq 35%and/or staining intensity score of 0-1.	OS	UA	3.350(1.490-7.510)
					MA	3.022(1.002-6.016)
Li SS	IHC	Nucleus	Score \leq 4	OS	UA	1.170(0.720-1.900)
					MA	1.628(1.060–2.500)

Table 3. Subgroup analyses of the association between LKB1 expression and OS after stratification by statistical analysis method, LKB1 assay method, region, cancer type, and intracellular staining location.

Stratification criterion	Value	HR(95%CI)	P value	Heterogeneity	
				I ²	P value
Analysis method	Univariate	1.63(1.35-1.97)	<0.001	74%	<0.001
	Multivariate	1.61(1.26-2.06)	<0.001	81%	<0.001
Assay method	IHC	1.58(1.33-1.88)	<0.001	76%	<0.001
Region	Asian	1.70(1.42-2.05)	<0.001	77%	<0.001
	Not Asian	1.15(0.63-2.08)	0.65	75%	0.007
Cancer type	Lung	2.07(1.60-2.69)	<0.001	53%	0.09
	Breast	1.26(1.15-1.37)	<0.001	79%	<0.001
	Gastric	2.11(1.60-3.01)	<0.001	0%	0.41
	Pancreatic	2.16(1.53-3.05)	<0.001	0%	0.76
	Hepatocellular carcinoma	1.27(0.84-1.94)	0.26	89%	<0.001
Staining position	The others	1.63(1.35-1.96)	<0.001	79%	<0.001
	Both nucleus and cytoplasm	1.50(1.31-1.17)	<0.001	80%	<0.001
	Cytoplasm	1.78(1.49-2.13)	<0.001	77%	<0.001
	Nucleus	1.25(0.85-1.85)	0.26	0%	0.65
	The others	1.36(1.25-1.47)	<0.001	75%	<0.001
NOS scores	High quality	1.53(1.19-1.96)	<0.001	77%	<0.001
	Intermediate quality	1.79(1.36-1.92)	<0.001	75%	<0.001

Table 4. Meta-analysis results of decreased LKB1 expression and patient's prognosis

prognosis	Analysis method	HR(95%CI)	<i>P</i> value	Hetherogeneity	
				<i>I</i> ²	<i>P</i> value
OS	Univariate analysis	1.63(1.35-1.97)	<i>P</i> < 0.01	74.0%	<i>P</i> < 0.001
	Multivariate analysis	1.61(1.26–2.06)	<i>P</i> < 0.001	81.0%	<i>P</i> < 0.001
RFS	Univariate analysis	1.44(0.65-3.17)	<i>P</i> = 0.37	85%	<i>P</i> < 0.001
	Multivariate analysis	1.02(0.42-2.47)	<i>P</i> = 0.97	95%	<i>P</i> < 0.001
DFS	Univariate analysis	1.49(0.73-3.01)	<i>P</i> = 0.27	78%	<i>P</i> = 0.001

For peer review only

Table 5. Meta-analysis of the association of decreased LKB1 expression with clinicopathological characteristics

	OR(95%CI)	<i>P</i> value	Heterogeneity		
			Q test	<i>I</i> ²	<i>P</i> value
Age(≥ 60 , < 60)	0.78(0.57-1.05)	<i>P</i> = 0.10	4.04	0%	0.78
Sex(Male, Female)	0.97(0.78-1.19)	<i>P</i> = 0.76	9.06	0%	0.77
Tumor differentiation(Poor, Well)	1.17(1.14-2.55)	<i>P</i> < 0.01	59.5	75%	<0.001
Tumor size(T3-T4, T1-T2)	1.68(1.24-2.27)	<i>P</i> < 0.01	43.34	61%	<0.001
Lymph node metastasis(Yes, No)	1.43(1.26-1.62)	<i>P</i> < 0.01	58.41	74%	<0.001
TNM stage(III-IV, I - II)	1.80(1.56-2.07)	<i>P</i> < 0.01	88.8	81%	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Fig 1. Flow diagram of the eligible studies

Fig 1. Flow diagram of the eligible studies

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig 2. Forest plot of the association between decrease LKB1 expression and OS.

Fig 2. Forest plot of the association between decrease LKB1 expression and OS

257x211mm (96 x 96 DPI)




Fig 3. Sensitivity analysis of OS in the meta-analysis

Fig 3. Sensitivity analysis of OS in the meta-analysis

257x211mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig 4. Funnel plot for the potential publication bias

Fig 4. Funnel plot for the potential publication bias

257x148mm (96 x 96 DPI)

Supplement table 1. LKB1 expression and clinicopathological characteristics.

Study	LKB1 expression	Age		Sex		Tumor differentiation		Tumor size		Lymph node metastasis		TNM stage	
		≥60	<60	Male	Female	Poor	Well	T3-T4	T1-T2	Yes	No	III-IV	I - II
Huang YH	Low	-	-	26	5	23	8	15	16	-	-	19	12
	High	-	-	31	8	17	22	20	19	-	-	27	12
He TY	Low	-	-	-	-	-	-	-	-	-	-	-	-
	High	-	-	-	-	-	-	-	-	-	-	-	-
Bouchekio ua-Bouzag hou K	Low (cytoplasmic staining)	-	-	-	-	69	25	26	68	50	44	-	-
	High	-	-	-	-	54	6	18	42	38	22	-	-
	Low(nuclear staining)	-	-	-	-	83	19	34	68	63	39	-	-
ShenZ	Low	-	-	-	-	35	3	13	25	-	-	-	-
	High	-	-	-	-	69	14	11	73	-	-	-	-
Tsai LH	Low	-	-	25	19	-	-	9	35	35	9	28	16
	High	-	-	41	30	-	-	9	62	31	40	24	47
Jiang LL	Low	16	17	17	16	23	10	-	-	18	15	12	21
	High	49	60	65	44	34	75	-	-	44	65	23	86
Yang JY	Low	-	-	16	20	32	4	35	1	17	19	16	20
	High	-	-	101	68	159	10	132	37	45	124	31	138
Calles A	Low	-	-	14	28	-	-	-	-	-	-	-	-
	High	-	-	25	59	-	-	-	-	-	-	-	-
Wang JH	Low	-	-	122	65	162	25	112	100	76	111	117	70
	High	-	-	93	46	90	49	63	51	42	97	56	83
Morton JP	Low	-	-	-	-	-	-	-	-	-	-	-	-
	High	-	-	-	-	-	-	-	-	-	-	-	-
Ding XM	Low	12	12	13	11	-	-	9	15	3	21	22	2
	High	21	17	14	24	-	-	7	31	8	20	15	23
Yang XW	Low	52	24	60	16	62	14	57	19	59	17	48	19
	High	16	8	20	4	20	4	13	11	7	17	6	11
Wu CC	Low	17	24	32	9	-	-	-	-	-	-	26	15
	High	25	27	45	7	-	-	-	-	-	-	32	20
Yin M	Low	43	35	54	24	57	21	71	7	56	22	68	20
	High	19	13	23	9	12	20	24	8	11	21	12	20

1														
2														
3														
4	Huang Y	Low	51	17	-	-	-	-	65	26	64	27	80	11
5		High	40	7	-	-	-	-	16	8	8	16	10	14
6	Ma LG	Low	51	22	60	13	60	13	48	25	24	49	31	42
7		high	36	11	36	11	24	23	24	23	5	42	6	41
8	Chen IC	low	-	-	-	-	126	25	16	145	67	91	23	138
9		High	-	-	-	-	311	81	34	372	152	253	57	351
10		Low	-	-	-	-	83	2	6	82	56	32	36	52
11		High	-	-	-	-	177	12	15	174	106	83	66	123
12		Low	-	-	-	-	457	37	20	474	241	253	85	369
13		High	-	-	-	-	459	35	26	468	235	259	88	406
14		Low	-	-	-	-	392	49	29	451	241	238	88	393
15		High	-	-	-	-	398	46	24	446	213	260	85	388
16	Li DZ	Low	-	-	26	12	6	32	-	-	-	-	-	-
17		High	-	-	16	17	1	32	-	-	-	-	-	-
18	Huang YH	Low	-	-	56	36	-	-	52	40	-	-	77	15
19		High	-	-	54	34	-	-	20	68	-	-	43	55
20	HamdyA.	Low	-	-	-	-	-	-	-	-	-	-	-	-
21	Azim													
22		High	-	-	-	-	-	-	-	-	-	-	-	-
23	Lu JL	Low	-	-	-	-	-	-	-	-	-	-	47	31
24		High	-	-	-	-	-	-	-	-	-	-	11	20
25	He SS	Low	-	-	-	-	-	-	-	-	-	-	-	-
26		High	-	-	-	-	-	-	-	-	-	-	-	-
27	Ma JJ	Low	29	33	40	22	27	35	44	18	51	11	28	34
28		High	30	17	31	16	19	28	18	29	29	18	9	38
29	Lee SW	Low	-	-	-	-	-	-	-	-	-	-	-	-
30		High	-	-	-	-	-	-	-	-	-	-	-	-
31	Sun JJ	Low	60	47	79	28	78	29	73	34	60	47	55	52
32		High	28	20	42	6	38	10	22	26	16	32	8	40
33														
34														
35														
36														
37														
38														
39														
40														
41														
42														
43														
44														
45														
46														
47														
48														
49														
50														
51														
52														
53														
54														
55														
56														
57														
58														
59														
60														

S2 Table. Newcastle-Ottawa Scale (NOS) for quality assessment in meta-analysis.**Selection**

(1) Representativeness of the exposed cohort

(a) Truly representative of the cancer patients in the community (1 star)

(b) Somewhat representative of the cancer patients in the community (1 star)

(c) Selected group of users (e.g., nurses, volunteers)

(d) No description of the derivation of the cohort

(2) Selection of the non-exposed cohort

(a) Drawn from the same community as the exposed cohort (1 star)

(b) Drawn from a different source

(c) No description of the derivation of the non-exposed cohort

(3) Ascertainment of exposure (proof of cancer and LKB1 measurement)

(a) Secure record (e.g., surgical records or pathological diagnosis) (1 star)

(b) Structured interview (1 star)

(c) Written self-report

(d) No description

(4) Demonstration that outcome of interest was not present at start of study

(a) Yes (1 star)

(b) No

Comparability

(1) Comparability of cohorts based on the design or analysis

(a) The age between exposed cohort and non-exposed cohort had no significant difference (1 star)

(b) The sex (or grade, stage, etc.) between exposed cohort and non-exposed cohort had no significant difference (1 star)

Outcome

(1) Assessment of outcome (death or recurrence)

(a) Independent blind assessment (1 star)

(b) Record linkage (1 star)

(c) Self-report

(d) No description

(2) Was follow-up long enough for outcomes to occur? (death or recurrence)

(a) Yes (at least 3 years) (1 star)

(b) No

(3) Adequacy of follow-up of cohorts

(a) Complete follow-up—all subjects accounted for (1 star)

(b) Subjects lost to follow-up unlikely to introduce bias—small number lost (less than 25%) or description provided of those lost (1 star)

(c) Follow-up rate less than 75% and no description of those lost

(d) No statement

Note: a maximum of one “star” for each item within the “Selection” and “Outcome” categories, maximum of two “stars” for “Comparability”.

S3 Table. Quality assessment of the 25 included studies according to the NOS.

Study	Year	Country	Type of cancer	Selection/4	Comparability/2	Outcome/3	Total score
Ding XM	2005	China	Lung adenocarcinoma	1+1+1+0=3	1+1=2	1+1+1=3	8
Tsai LH	2013	China	Lung adenocarcinomas	1+1+1+0=3	1+1=2	1+1+0=2	7
Jiang LL	2014	China	Non-small cell lung cancer	1+1+1+0=3	1+1=2	1+1+0=2	7
Calles A	2015	USA	Lung adenocarcinoma	1+1+1+0=3	1+1=2	1+1+0=2	7
Shen Z	2002	China	Breast carcinoma	1+1+1+0=3	1+0=1	1+1+0=2	6
Bouchekioua-B ouzaghrou K	2014	France	Breast cancer	1+1+1+0=3	1+1=2	1+1+0=2	7
Chen IC	2016	China	Breast cancer	1+1+1+0=3	1+0=1	1+1+0=2	6
		UK and Canada	Breast cancer	1+1+1+0=3	0+0=0	1+1+0=2	5
HamdyA.Azim	2016	Egypt	Breast Cancer	1+1+1+0=3	0+0=0	1+1+0=2	6
Morton JP	2010	UK	Pancreatic cancer	1+1+1+0=3	0+0=0	1+1+1=3	6
Yang JY	2015	China	Pancreatic ductal adenocarcinoma	1+1+1+0=3	1+1=2	1+1+0=2	7
Li DZ	2018	China	Pancreatic neuroendocrine tumor	1+1+1+0=3	1+1=2	1+1+1=3	8
Yang XW	2012	China	Gastric Cancer	1+1+1+0=3	1+1=2	1+1+0=2	7
Huang Y	2014	China	Gastric carcinoma	1+1+1+0=3	1+0=1	1+1+0=2	6
Ma LG	2016	China	Gastric Cancer	1+1+1+0=3	1+1=2	1+1+1=3	8
Sun JJ	2016	China	Gastric Cancer	1+1+1+0=3	1+0=1	1+1+0=2	6
Yin M	2017	China	Gastric Cancer	1+1+1+0=3	1+0=1	1+1+1=3	7
Huang YH	2013	China	Hepatocellular carcinoma	1+1+1+0=3	1+1=2	1+1+0=2	7
Lee SW	2015	China	Hepatocellular carcinoma	1+1+1+0=3	1+1=2	1+1+0=2	7
Wu CC	2018	China	Hepatocellular carcinoma	1+1+1+0=3	1+0=1	1+1+1=3	7

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Wang JH	2015	China	Intrahepatic cholangiocarcinoma	1+1+1+0=3	1+1=2	1+1+1=3	8
Ma JJ	2014	China	Esophagus squamous cancer	1+1+1+0=3	1+1=2	1+1+1=3	8
He TY	2014	China	Colorectal cancer	1+1+1+0=3	0+0=0	1+1+0=2	5
Lu JL	2015	China	Prostate Cancer	1+1+1+0=3	1+0=1	1+1+1=3	7
Huang JH	2017	China	Glioma	1+1+1+0=3	1+1=2	1+1+1=3	8
He SS	2017	China	Laryngeal squamous cell carcinoma	1+1+1+0=3	1+1=2	1+1+1=3	8

For peer review only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a meta-analysis.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n/a
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	5-6



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>